guide arm #3

Guide arm #3 is a proprietary, undisclosed cell surface antigen targeted by Virtuoso Therapeutics as part of their 'Guide x Effector' bispecific antibody platform. In this platform, the 'guide arm' is an antibody component designed to bind with high affinity to an antigen that is overexpressed on target cells, such as tumor cells, to enhance the selectivity and potency of the therapeutic through avidity-driven binding. The specific program involving this target is a bispecific antibody combining a CD47-targeting effector arm with the guide arm #3, aimed at treating solid tumors. By pairing a potent effector like CD47 with a selective guide arm, the therapy seeks to minimize off-target effects on healthy cells, such as red blood cells, while maximizing anti-tumor activity. As of current reports, the molecular identity of guide arm #3 remains undisclosed by the company, though it is distinct from other guide antigens in their pipeline such as ICAM-1 and EpCAM.

Other names

Undisclosed guide arm 3Virtuoso guide arm 3GA3

Bispecific antibody targeting with avidity-driven selectivity and CD47-mediated immune checkpoint inhibition